research Hair today, gone tomorrow
Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.
Search
for
Sort by
Research
900-930 / 1000+ results 
research Nitric oxide-releasing nanocarriers integrated with ginsenoside compound K in dissolvable microneedles for androgenetic alopecia
The new microneedle system promotes hair growth by improving the hair follicle environment.
research PD49-03 IS TADALAFIL ASSOCIATED WITH DECREASED RISK OF MAJOR ADVERSE CARDIAC EVENTS OR VENOUS THROMBOEMBOLISM IN MEN WITH LOWER URINARY TRACT SYMPTOMS?
Tadalafil may reduce the risk of major heart events and blood clots in men with urinary symptoms.
research NOVEL NANOPARTICULATE SYSTEMS FOR IDIOPATHIC PULMONARY FIBROSIS: A REVIEW
Nanoparticles may improve treatment for lung disease by targeting cells better and reducing side effects.
research Reversal of andro-genetic alopecia in a male. A spironolactone effect?
A man's baldness improved possibly due to a medication that blocks male hormones.
research The Chinese State Food and Drug Administration has issued Sinovac Biotech a New Drug Certificate approving its split influenza vaccine
China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.
research The effects of methylated flavonoids on depression-like activity and pro-inflammatory cytokine thresholds in mice induced by repeated finasteride administration
Methylated flavonoids may effectively reduce depression and inflammation caused by finasteride.
research New-onset systemic lupus erythematosus beginning as class V lupus nephritis after COVID-19 vaccination
COVID-19 vaccination may trigger lupus in some people.
research NUDT15 polymorphism explains serious toxicity to azathioprine in Indian patients with chronic immune thrombocytopenia and autoimmune hemolytic anemia: a case series
The NUDT15 gene variant causes severe side effects from azathioprine in some Indian patients.
research Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: SYNERGY II study
Using mirabegron and solifenacin together is safe and more effective for treating overactive bladder than using either drug alone.
research Influencia del tratamiento con alfa bloqueantes e inhibidores de la 5 alfa reductasa en los hallazgos morfológicos e inmunohistoquímicos de la hiperplasia benigna de próstata
Finasteride treatment makes the prostate look more like a healthy one.
research 5α-Reductase inhibitors alter steroid metabolism and may contribute to insulin resistance, diabetes, metabolic syndrome and vascular disease: a medical hypothesis
Some hair loss and prostate drugs might increase the risk of diabetes and heart disease.
research 5 Alpha-Reductase Inhibitor
5 Alpha-Reductase Inhibitors reduce the effects of testosterone by blocking its conversion into a stronger form.
research Recurrent inverse necrotizing infundibular crystalline folliculitis
Recurrent NICF is a rare skin condition with unclear causes, involving follicle inflammation and crystal deposits.
research Redox-Modulatory and MET-Inhibitory Triad: Synergistic Cytotoxicity of L-cysteine, NAC, and MET Inhibition in Cervical Cancer Cells
Combining L-cysteine, NAC, and a MET inhibitor significantly kills cervical cancer cells.
research Synthesis and biological activity evaluation of new isatin-gallate hybrids as antioxidant and anticancer agents (in vitro) and in silico study as anticancer agents and coronavirus inhibitors
New isatin-gallate hybrids show promise as antioxidants, cancer treatments, and coronavirus inhibitors.
research Nanocarriers for Improved Delivery of Angiotensin-(1-7)
Nanocarriers like liposomes and cyclodextrins improve how angiotensin-(1-7) is delivered in the body.
research Lower urinary tract symptoms and functional ability in older adults: a community-based cross-sectional study
Early detection and treatment of urinary symptoms can help maintain functional ability in older adults.
research Systemic lupus erythematosus : from diagnosis to prognosis
Current SLE classifications need refinement, and the complement system is a key therapeutic target.
research Anabolic effects of testosterone are preserved during inhibition of 5α-reductase
Testosterone can build muscle and bone without enlarging the prostate when a specific enzyme is blocked.
research finasteride, n.
research Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink
Taking 5-α reductase inhibitors for prostate enlargement or hair loss does not significantly raise the risk of erectile dysfunction.
research JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
research Finasteride in polycythaemia
research Novel drugs of United States Food and Drug Administration approved in 2024
In 2024, the FDA approved 50 new drugs, including treatments for hair loss, anemia, high blood pressure, and Alzheimer's.
research Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.
research Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.
research Finasteride/flibanserin
research Phosphodiesterase inhibitors used in androgenic alopecia as a possible risk factor for testicular tumor
research Pathogenetic justification of the use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia.
5-alpha reductase inhibitors help with benign prostatic hyperplasia but don't cure it, and more research is needed.